368 related articles for article (PubMed ID: 22446156)
1. Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis.
Bonroy C; Van Praet J; Smith V; Van Steendam K; Mimori T; Deschepper E; Deforce D; Devreese K; De Keyser F
J Immunol Methods; 2012 May; 379(1-2):53-60. PubMed ID: 22446156
[TBL] [Abstract][Full Text] [Related]
2. Fluoroenzymeimmunoassay to detect systemic sclerosis-associated antibodies: diagnostic performance and correlation with conventional techniques.
Bonroy C; Smith V; Van Steendam K; Van Praet J; Deforce D; Devreese K; De Keyser F
Clin Exp Rheumatol; 2012; 30(5):748-55. PubMed ID: 22765957
[TBL] [Abstract][Full Text] [Related]
3. Serological profile of patients with systemic sclerosis.
Wielosz E; Dryglewska M; Majdan M
Postepy Hig Med Dosw (Online); 2014 Aug; 68():987-91. PubMed ID: 25228505
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to fibrillarin, PM-Scl and RNA polymerase III detected by ELISA assays in patients with systemic sclerosis.
Villalta D; Morozzi G; Tampoia M; Alpini C; Brusca I; Salgarolo V; Papisch W; Bizzaro N
Clin Chim Acta; 2010 May; 411(9-10):710-3. PubMed ID: 20138166
[TBL] [Abstract][Full Text] [Related]
5. Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.
Faucher B; Stein P; Granel B; Weiller PJ; Disdier P; Serratrice J; Harlé JR; Durand JM; Frances Y; Guis S; Pham T; Bardin N; Sanmarco M
Eur J Intern Med; 2010 Apr; 21(2):114-7. PubMed ID: 20206882
[TBL] [Abstract][Full Text] [Related]
6. Anti-PM/Scl-100 and anti-RNA-polymerase III antibodies in scleroderma.
Maes L; Blockmans D; Verschueren P; Westhovens R; De Beéck KO; Vermeersch P; Van den Bergh K; Burlingame RW; Mahler M; Bossuyt X
Clin Chim Acta; 2010 Jul; 411(13-14):965-71. PubMed ID: 20346932
[TBL] [Abstract][Full Text] [Related]
7. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients.
D'Aoust J; Hudson M; Tatibouet S; Wick J; ; Mahler M; Baron M; Fritzler MJ
Arthritis Rheumatol; 2014 Jun; 66(6):1608-15. PubMed ID: 24577935
[TBL] [Abstract][Full Text] [Related]
8. Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis.
Patterson KA; Roberts-Thomson PJ; Lester S; Tan JA; Hakendorf P; Rischmueller M; Zochling J; Sahhar J; Nash P; Roddy J; Hill C; Nikpour M; Stevens W; Proudman SM; Walker JG
Arthritis Rheumatol; 2015 Dec; 67(12):3234-44. PubMed ID: 26246178
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a novel particle-based multi-analyte technology for the detection of anti-fibrillarin antibodies.
Mahler M; Kim G; Roup F; Bentow C; Fabien N; Goncalves D; Palterer B; Fritzler MJ; Villalta D
Immunol Res; 2021 Jun; 69(3):239-248. PubMed ID: 33913080
[TBL] [Abstract][Full Text] [Related]
10. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA.
Mahler M; You D; Baron M; Taillefer SS; Hudson M; ; Fritzler MJ
Clin Chim Acta; 2011 Oct; 412(21-22):1937-43. PubMed ID: 21756890
[TBL] [Abstract][Full Text] [Related]
11. Test performance in systemic sclerosis: anti-centromere and anti-Scl-70 antibodies.
Spencer-Green G; Alter D; Welch HG
Am J Med; 1997 Sep; 103(3):242-8. PubMed ID: 9316557
[TBL] [Abstract][Full Text] [Related]
12. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
13. The clinical relevance of autoantibodies in scleroderma.
Ho KT; Reveille JD
Arthritis Res Ther; 2003; 5(2):80-93. PubMed ID: 12718748
[TBL] [Abstract][Full Text] [Related]
14. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
[TBL] [Abstract][Full Text] [Related]
15. Late onset systemic sclerosis with seronegativity: a rare presentation of an uncommon disease.
Saxena D; Jain D; Yadav M; Giri K; Yadav T; Jain P
Reumatismo; 2019 Oct; 71(3):166-170. PubMed ID: 31649382
[TBL] [Abstract][Full Text] [Related]
16. Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?
Benyamine A; Bertin D; Heim X; Granel B; Bardin N
Eur J Intern Med; 2017 Oct; 44():e42-e44. PubMed ID: 28781194
[No Abstract] [Full Text] [Related]
17. Detection of anti-U3-RNP/fibrillarin IgG antibodies by line immunoblot assay has comparable clinical significance to immunoprecipitation testing in systemic sclerosis.
Peterson LK; Jaskowski TD; Mayes MD; Tebo AE
Immunol Res; 2016 Apr; 64(2):483-8. PubMed ID: 26467972
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests.
Alkema W; Koenen H; Kersten BE; Kaffa C; Dinnissen JWB; Damoiseaux JGMC; Joosten I; Driessen-Diks S; van der Molen RG; Vonk MC; Smeets RL
Autoimmunity; 2021 May; 54(3):148-155. PubMed ID: 33818234
[TBL] [Abstract][Full Text] [Related]
19. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies.
Falkner D; Wilson J; Medsger TA; Morel PA
Arthritis Rheum; 1998 Jan; 41(1):74-80. PubMed ID: 9433872
[TBL] [Abstract][Full Text] [Related]
20. The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies.
Bonroy C; Smith V; Van Steendam K; Van Praet J; Deforce D; Devreese K; De Keyser F
Clin Chem Lab Med; 2013 Nov; 51(11):2151-60. PubMed ID: 23863700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
